Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes

The Transcriptional Regulation of the Human CYP2C Genes

(2012) Yuping Chen et al.   CURRENT DRUG METABOLISM

The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors

(2011) Steven Lane et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Evaluation of a CYP2C19 genotype panel on the GenMark eSensor® platform and the comparison to the Autogenomics Infiniti™ and Luminex CYP2C19 panels

(2011) Christine C. Lee et al.   CLINICA CHIMICA ACTA

Pharmacogenetics and Clopidogrel Response in Patients Undergoing Percutaneous Coronary Interventions

(2011) A L Beitelshees et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

(2011) J J Swen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans

(2011) M A Perera et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy

(2011) S A Scott et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

High Doses of Clopidogrel to Overcome Genetic Resistance

(2011) Jean-Philippe Collet et al.   JACC-Cardiovascular Interventions

Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis

(2011) Guillaume Cayla et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

PharmGKB summary

(2011) Stuart A. Scott et al.   Pharmacogenetics and Genomics

Responding to the Clopidogrel Warning by the US Food and Drug Administration

(2010) Dan M. Roden et al.   CIRCULATION

Human CYP2C8: Structure, Substrate Specificity, Inhibitor Selectivity, Inducers and Polymorphisms

(2010) Xin-Sheng Lai et al.   CURRENT DRUG METABOLISM

Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations

(2010) Rasmus S. Pedersen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Linkage disequilibrium between the CYP2C19*17 and CYP2C8*2 alleles in populations of African descent

(2010) Guilherme Suarez-Kurtz   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases

(2010) Stuart A. Scott et al.   HUMAN MUTATION

Clopidogrel Pharmacogenomics: Next Steps

(2010) Patrick Gladding et al.   JACC-Cardiovascular Interventions

Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

(2010) Jessica L. Mega et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements

(2010) Kendra A Ross et al.   JOURNAL OF HUMAN GENETICS

Genotyping

(2010) Paul A. Gurbel et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration

(2010) Jean-Sébastien Hulot et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”

(2010) David R. Holmes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis

(2010) Jessica L Mega et al.   LANCET

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

(2010) Lars Wallentin et al.   LANCET

CombinedCYP2C9,VKORC1andCYP4F2frequencies among racial and ethnic groups

(2010) Stuart A Scott et al.   PHARMACOGENOMICS

Population-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbase

(2010) Marianthi Georgitsi et al.   PHARMACOGENOMICS

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17

(2009) Alain Li-Wan-Po et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy

(2009) Alan R. Shuldiner   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

(2009) Elizabeth B Daily et al.   PHARMACOGENOMICS

CYP2C9*8is prevalent among African–Americans: implications for pharmacogenetic dosing

(2009) Stuart A Scott et al.   PHARMACOGENOMICS

Global variation in CYP2C8–CYP2C9 functional haplotypes

(2009) William C Speed et al.   PHARMACOGENOMICS JOURNAL

Warfarin Pharmacogenetics: CYP2C9 and VKORC1 Genotypes Predict Different Sensitivity and Resistance Frequencies in the Ashkenazi and Sephardi Jewish Populations

(2008) Stuart A. Scott et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

(2008) Jean-Philippe Collet et al.   LANCET

Cytochrome P-450 Polymorphisms and Response to Clopidogrel

(2008) Jessica L. Mega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic Determinants of Response to Clopidogrel and Cardiovascular Events

(2008) Tabassome Simon et al.   NEW ENGLAND JOURNAL OF MEDICINE